Pregnancy Postpartum
Conditions
Keywords
Hemostasis, pregnancy, postpartum, point of care, coagulopathy
Brief summary
Postpartum hemorrhage (PPH) remains the leading cause of maternal death. PPH associated coagulopathy varies and their treatments (tranexamic acid, fibrinogen concentrates,plasma, platelets need to be targeted and administrated early. Point of care hemostasis devices are helpful to develop this strategy. Quantra® (STAGO BIOCARE) use an innovative method to detect the clot formation. Pregnancy and non-hemorrhagic postpartum reference ranges are missing. The objective of this study is to establish these norms needed to elaborate thereafter the thresholds to be targeted in PPH conditions.
Interventions
None listed
Sponsors
University Hospital, Lille
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Healthy pregnant woman (indemne of any chronic pathology neither obstetrical pathology) * Delivering vaginally without postpartum hemorrhage for 60 patients * Delivering through a programmed C-section for 20 patients * Having given a non-opposition agreement to participate in the study. * Major patient with social insurance
Exclusion criteria
* Any acute or chronic hemostasis pathology before pregnancy or during pregnancy instrumental delivery or cesarean section Postpartum bleeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Description of the QUANTRA® parameters range intervals before and after vaginal delivery | At admission (= before delivery ) |
Secondary
| Measure | Time frame |
|---|---|
| Description of the QUANTRA® parameters range intervals before and after vaginal delivery | At 30 up to 60 minutes after birth and placental removal. |
| Comparison between end of pregnancy and immediate postpartum reference values (both vaginal and caesarean deliveries) | At 30 up to 60 minutes after birth |
Countries
France
Outcome results
None listed